Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

N-Acetyl Cysteine and Improved Dopamine Transporter Binding

Doses used in studies

mg/day: 1,000 (median 1,000, IQR 1,000–1,000) — 1 study

Time to effect

Median: 3 months · IQR 3 months–3 months · Range 3 months–3 months — Reported in 1 of 2 studies

Safety in these studies

Overall tolerabilityReported
NAC demonstrated a favorable safety profile across all conditions.
from: N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translatio

2 of 2 papers

N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders.
- 2026-03-27
- Systematic Review
- International journal of molecular sciences 27(7)
- - Robert Mîndreanu
  - Irina Camelia Chiș
  - Alexandra Sevastre-Berghian
  - Cezar Login
  - Adina Stan
  - Teodora Stan
  - Simona Clichici
  - Șoimița Suciu
- PubMed: 41977262
- DOI: 10.3390/ijms27073076
4 Insights on
- Improved Dopamine Transporter Binding
- High evidence
- Rigorous Journal
- Clinical
for PD, where combined intravenous/oral NAC improved dopamine transporter binding
Effect
Beneficial
Effect size
Moderate
Significant
Yes
N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease.
- 2019-07-17
- RCT
- Clinical pharmacology and therapeutics 106(4)
- - Daniel A Monti
  - George Zabrecky
  - Daniel Kremens
  - Tsao-Wei Liang
  - Nancy A Wintering
  - Anthony J Bazzan
  - Li Zhong
  - Brendan K Bowens
  - Inna Chervoneva
  - Charles Intenzo
  - Andrew B Newberg
- PubMed: 31206613
- DOI: 10.1002/cpt.1548
4 Insights on
- Improved Dopamine Transporter Binding
- High evidence
- Highly Cited
- Clinical
In the NAC group, significantly increased DAT binding was found in the caudate and putamen (mean increase from 3.4% to 8.3%) compared with controls (P < 0.05)
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
50 mg/kg weekly intravenous infusions plus 500 mg oral twice per day for 3 months